Literature DB >> 8732293

Effect of cyclo-oxygenase inhibitors and modulators of cyclic AMP formation on lipopolysaccharide-induced neutrophil infiltration in mouse lung.

V L Goncalves de Moraes1, B Boris Vargaftig, J Lefort, A Meager, M Chignard.   

Abstract

1. The adult respiratory distress syndrome (ARDS) is an acute lung inflammation developed after direct or indirect contact with pathogenic agents. In the present study, a mouse model was developed to mimic this condition using aerosolized bacterial lipopolysaccharide (LPS) and to investigate the mechanisms involved in the lung inflammatory response. 2. Inhalation of LPS led to a time and dose-dependent increase in tumour necrosis factor-alpha (TNF-alpha) production and neutrophil recruitment into the bronchoalveolar lavage fluid (BALF) of Balb/c mice. Under the same conditions, neutrophil infiltration was also found in the BALF of the LPS-sensitive mouse strain C3H/HeN, but was absent in the LPS-resistant strain C3H/HeJ. Intranasal administration of murine recombinant TNF-alpha also triggered neutrophil recruitment. 3. One hour after inhalation of LPS, half of the maximal level of TNF-alpha was measured in the BALF, but only a few neutrophils were detected at this time. The peak TNF-alpha concentration was reached at 3 h, when the neutrophil amount started to increase. At 24 h, maximal neutrophil number was found in the BALF and TNF-alpha was no longer present. 4. Pretreatment of mice under different experimental conditions demonstrated that: (a) cycloheximide almost completely blocks both neutrophil recruitment and TNF-alpha production; (b) anti TNF-alpha antibodies block neutrophil recruitment; (c) indomethacin or aspirin enhance by two fold neutrophil recruitment; (d) indomethacin significantly increases TNF-alpha production 1 h after inhalation of LPS; (e) dibutyryl cyclic AMP and prostaglandin E2 (PGE2) block both neutrophil recruitment and TNF-alpha production. 5. It is concluded that aerosolized LPS in mice triggers an acute lung inflammation which can be used as a potential model of inhalational ARDS and that, strategies leading to the elevation of cyclic AMP levels in vivo can be effective in modulating LPS-induced TNF-alpha synthesis and neutrophil recruitment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732293      PMCID: PMC1909558          DOI: 10.1111/j.1476-5381.1996.tb15356.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  The intratracheal administration of endotoxin and cytokines. I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced inflammatory infiltrate.

Authors:  T R Ulich; L R Watson; S M Yin; K Z Guo; P Wang; H Thang; J del Castillo
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

2.  Endotoxin-mediated pulmonary endothelial cell injury.

Authors:  B O Meyrick
Journal:  Fed Proc       Date:  1986-01

3.  Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown.

Authors:  V Mahadevan; S T Malik; A Meager; W Fiers; G P Lewis; I R Hart
Journal:  Cancer Res       Date:  1990-09-01       Impact factor: 12.701

4.  Regulation of tumor necrosis factor expression in a macrophage-like cell line by lipopolysaccharide and cyclic AMP.

Authors:  S M Taffet; K J Singhel; J F Overholtzer; S A Shurtleff
Journal:  Cell Immunol       Date:  1989-05       Impact factor: 4.868

5.  Dynamics of dibutyryl cyclic AMP- and prostaglandin E2-mediated suppression of lipopolysaccharide-induced tumor necrosis factor alpha gene expression.

Authors:  R N Spengler; M L Spengler; P Lincoln; D G Remick; R M Strieter; S L Kunkel
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

6.  Shock and tissue injury induced by recombinant human cachectin.

Authors:  K J Tracey; B Beutler; S F Lowry; J Merryweather; S Wolpe; I W Milsark; R J Hariri; T J Fahey; A Zentella; J D Albert
Journal:  Science       Date:  1986-10-24       Impact factor: 47.728

7.  Regulation of macrophage tumoricidal function: a role for prostaglandins of the E series.

Authors:  R M Schultz; N A Pavlidis; W A Stylos; M A Chirigos
Journal:  Science       Date:  1978-10-20       Impact factor: 47.728

8.  Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha.

Authors:  I Görgen; T Hartung; M Leist; M Niehörster; G Tiegs; S Uhlig; F Weitzel; A Wendel
Journal:  J Immunol       Date:  1992-08-01       Impact factor: 5.422

9.  Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes.

Authors:  W J Ming; L Bersani; A Mantovani
Journal:  J Immunol       Date:  1987-03-01       Impact factor: 5.422

10.  Intratracheal administration of endotoxin and cytokines. VI. Antiserum to CINC inhibits acute inflammation.

Authors:  T R Ulich; S C Howard; D G Remick; A Wittwer; E S Yi; S Yin; K Guo; J K Welply; J H Williams
Journal:  Am J Physiol       Date:  1995-02
View more
  27 in total

1.  Low-level laser therapy (LLLT) acts as cAMP-elevating agent in acute respiratory distress syndrome.

Authors:  Flávia Mafra de Lima; Leonardo M Moreira; A B Villaverde; Regiane Albertini; Hugo C Castro-Faria-Neto; Flávio Aimbire
Journal:  Lasers Med Sci       Date:  2010-12-24       Impact factor: 3.161

2.  Host genetics of Bordetella pertussis infection in mice: significance of Toll-like receptor 4 in genetic susceptibility and pathobiology.

Authors:  H A Banus; R J Vandebriel; H de Ruiter; J A M A Dormans; N J Nagelkerke; F R Mooi; B Hoebee; H J van Kranen; T G Kimman
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Airway reactivity, inflammatory cell influx and nitric oxide in guinea-pig airways after lipopolysaccharide inhalation.

Authors:  T J Toward; K J Broadley
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

4.  Down-regulation by prostaglandins of type-II phospholipase A2 expression in guinea-pig alveolar macrophages: a possible involvement of cAMP.

Authors:  D Vial; L Arbibe; N Havet; C Dumarey; B Vargaftig; L Touqui
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

5.  Role of p38 MAP kinase in LPS-induced airway inflammation in the rat.

Authors:  E B Haddad; M Birrell; K McCluskie; A Ling; S E Webber; M L Foster; M G Belvisi
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

6.  Contribution of alveolar type II cell-derived cyclooxygenase-2 to basal airway function, lung inflammation, and lung fibrosis.

Authors:  Jennifer Cheng; Ryan T Dackor; J Alyce Bradbury; Hong Li; Laura M DeGraff; Lee K Hong; Debra King; Fred B Lih; Artiom Gruzdev; Matthew L Edin; Gregory S Travlos; Gordon P Flake; Kenneth B Tomer; Darryl C Zeldin
Journal:  FASEB J       Date:  2015-09-22       Impact factor: 5.191

Review 7.  Prevention or Treatment of Ards With Aspirin: A Review of Preclinical Models and Meta-Analysis of Clinical Studies.

Authors:  Bernardo Amisa Panka; Harm-Jan de Grooth; Angélique Maria Elisabeth Spoelstra-de Man; Mark R Looney; Pieter-Roel Tuinman
Journal:  Shock       Date:  2017-01       Impact factor: 3.454

Review 8.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

9.  The EP1/EP3 receptor agonist 17-pt-PGE2 acts as an EP4 receptor agonist on endothelial barrier function and in a model of LPS-induced pulmonary inflammation.

Authors:  Anna Theiler; Viktoria Konya; Lisa Pasterk; Jovana Maric; Thomas Bärnthaler; Ilse Lanz; Wolfgang Platzer; Rufina Schuligoi; Akos Heinemann
Journal:  Vascul Pharmacol       Date:  2016-09-21       Impact factor: 5.773

10.  Cytosolic phospholipase A2alpha mediates Pseudomonas aeruginosa LPS-induced airway constriction of CFTR -/- mice.

Authors:  Yong-Zheng Wu; Mohammad Abolhassani; Mario Ollero; Fariel Dif; Naonori Uozumi; Micheline Lagranderie; Takao Shimizu; Michel Chignard; Lhousseine Touqui
Journal:  Respir Res       Date:  2010-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.